Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments
Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its ability to access over $10 million in undrawn equity lines of credit Carl Schwartz, the CEO of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has recently published a…